These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 4027117)
21. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487 [TBL] [Abstract][Full Text] [Related]
22. The effects of dose, route, and repeated dosing on the disposition and kinetics of tetrabromobisphenol A in male F-344 rats. Kuester RK; Sólyom AM; Rodriguez VP; Sipes IG Toxicol Sci; 2007 Apr; 96(2):237-45. PubMed ID: 17234645 [TBL] [Abstract][Full Text] [Related]
23. Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. Mikus G; Fischer C; Heuer B; Langen C; Eichelbaum M Br J Clin Pharmacol; 1987 Nov; 24(5):561-9. PubMed ID: 3435690 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent. Klotz U; Müller-Seydlitz P; Heimburg P Clin Pharmacokinet; 1978; 3(5):407-18. PubMed ID: 699462 [TBL] [Abstract][Full Text] [Related]
26. Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. Rubin GM; Waschek JA; Pond SM; Effeney DJ; Tozer TN J Pharmacokinet Biopharm; 1987 Dec; 15(6):615-31. PubMed ID: 3450845 [TBL] [Abstract][Full Text] [Related]
27. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [ Guerini E; Schadt S; Greig G; Haas R; Husser C; Zell M; Funk C; Hartung T; Gloge A; Mallalieu NL Xenobiotica; 2017 Feb; 47(2):144-153. PubMed ID: 27123695 [TBL] [Abstract][Full Text] [Related]
28. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Perucca E; Cloyd J; Critchley D; Fuseau E Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564 [TBL] [Abstract][Full Text] [Related]
29. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Crevoisier C; Delisle MC; Joseph I; Foletti G Eur Neurol; 2003; 49(3):173-7. PubMed ID: 12646763 [TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and disposition of carvedilol in humans. Neugebauer G; Akpan W; von Möllendorff E; Neubert P; Reiff K J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S85-8. PubMed ID: 2454375 [TBL] [Abstract][Full Text] [Related]
32. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179 [TBL] [Abstract][Full Text] [Related]
33. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002 [TBL] [Abstract][Full Text] [Related]
34. Phencyclidine (PCP) disposition kinetics in dogs as a function of dose and route of administration. Woodworth JR; Owens SM; Mayersohn M J Pharmacol Exp Ther; 1985 Sep; 234(3):654-61. PubMed ID: 4032285 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657 [TBL] [Abstract][Full Text] [Related]
36. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Säwe J Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045 [TBL] [Abstract][Full Text] [Related]
37. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding. Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152 [TBL] [Abstract][Full Text] [Related]
39. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976 [TBL] [Abstract][Full Text] [Related]